| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PF-750 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.008 |
| mRNA | Elesclomol | GDSC1000 | pan-cancer | AAC | -0.091 | 0.009 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | -0.15 | 0.01 |
| mRNA | EX-527 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.01 |
| mRNA | AZD6244 | CTRPv2 | pan-cancer | AAC | -0.098 | 0.01 |
| mRNA | THZ-2-49 | GDSC1000 | pan-cancer | AAC | -0.078 | 0.01 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.085 | 0.01 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | -0.12 | 0.01 |
| mRNA | selumetinib:UNC0638 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.095 | 0.01 |
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | -0.13 | 0.01 |